ArticleJournal of cardiothoracic surgery2026
Heart and combined heart-liver transplantation in Asian patients with Fontan circulatory failure: a single-center experience.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe Fontan procedure improves survival in single-ventricle patients, but some progress to Fontan circulatory failure (FCF) with limited treatment options. Fontan-associated liver disease (FALD) further complicates management and raises uncertainty regarding the choice between isolated heart transplantation (HT) and combined heart-liver transplantation (CHLT). Data from Asian populations are limited, and this study aimed to provide additional evidence on transplantation outcomes in this population.
methodsA single-center retrospective study in China, describing the clinical characteristics, surgical procedures, and outcomes of six consecutive HT patients and one CHLT patient with FCF. The study was conducted between August 2017 and October 2025.
resultsThere were no perioperative deaths and 30‑day survival was 100%. One patient died on postoperative day 60 due to severe pulmonary infection with multiorgan failure, resulting in overall survival of 85.7%, with a median follow-up duration of 71 months (IQR, 6.5-77.0). Cardiac graft function was preserved in all survivors, with improvement in New York Heart Association (NYHA) class from IV preoperatively to I-II. The CHLT recipient experienced initial cardiac graft dysfunction that required intra-aortic balloon pump (IABP) support and renal dialysis. The patient subsequently recovered, with stable function of the cardiac and hepatic allografts, and preserved native renal function. Liver function tests normalized, and protein-losing enteropathy resolved.
conclusionsThis study demonstrates that both HT and CHLT are feasible for carefully selected patients with FCF. Favorable outcomes likely reflect timely referral, rigorous candidate selection with systematic evaluation of FALD and end-organ function, and proactive management of comorbidities. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.